Skip to content
DataLookout
Menu

Also listed under Myeloproliferative Disorders

ClinicalTrials.gov term: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Chronic Myeloid Leukemia (CML) clinical trials

Get alerts when Chronic Myeloid Leukemia (CML) trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08

What changed in the last 30 days

20 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 9 with minor changes only.

  1. Minor: K2SPIRIT · Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation Poitiers University HospitalNot specified NCT06646978
  2. Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated M.D. Anderson Cancer CenterPhase 1 NCT02530034
  3. Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations Alliance for Clinical Trials in OncologyNot specified NCT05334069
  4. Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026 National Cancer Institute (NCI)Phase 1 NCT06904066
  5. Notable: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Primary completion pushed from Sep 2026 to Sep 2027 University of FloridaPhase 1/2 NCT05322850
  6. Notable: Prophylactic DLI-X for Leukemia Relapse After HCT Recruitment opened University of ArizonaPhase 1 NCT07254793
  7. Notable: Allow Access to Imatinib · on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Results posted: Oct 29, 2026 Novartis PharmaceuticalsPhase 4 NCT01742299
  8. Minor: Allogeneic iNKT Cell Therapy (agenT-797) After SCT Start date pushed from Oct 2026 to Nov 2026 University of Wisconsin, MadisonPhase 1 NCT07758218
  9. Minor: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation · High-Risk Hematologic Diseases Interventions modified Fred Hutchinson Cancer CenterPhase 2 NCT06013423
  10. Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030 City of Hope Medical CenterPhase 1 NCT07020533
  11. Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027 City of Hope Medical CenterPhase 2 NCT06059391
  12. Minor: Cord Blood Transplant · Blood Cancers Enrollment closed, study ongoing Memorial Sloan Kettering Cancer CenterPhase 2 NCT05884333
  13. Minor: ASC4Young · Asciminib Safety and Efficacy in Young · Chronic Myeloid Leukemia in the Gulf Region Primary and study completion pushed from Jun 30, 2027 to Jul 30, 2027 Novartis PharmaceuticalsNot specified NCT07681258
  14. Notable: TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients Primary completion pushed from Mar 30, 2027 to Dec 31, 2027 Shenzhen TargetRx Co., Ltd.Phase 1 NCT06088888
  15. Notable: CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation Study completion date changed from estimate of Dec 31, 2025 to Sep 8, 2026 Otsuka Beijing Research InstitutePhase 2 NCT04233346
  16. Minor: Condition Vasoregulation Function Endothelium · CML Getting TKI II Generation Bosutinib Trial completed Samara State Medical UniversityNot specified NCT05682924
  17. Notable: CARDINAL · MK-4208/TERN-701 · Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) Enrollment increased: 180 → 330 participants Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 NCT06163430
  18. Minor: Asciminib · Ph+ CML-CP Trial sites expanded: 30 → 34 locations Novartis PharmaceuticalsPhase 2 NCT07354074
  19. Notable: Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Primary and study completion dates pushed to Jun 2027 Obafemi Awolowo UniversityPhase 2 NCT07022743
  20. Notable: PHARM-LMC · Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia Primary completion pushed from Nov 1, 2025 to Dec 31, 2027 Centre Hospitalier Universitaire de Saint EtienneNot applicable NCT05130138
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-14 NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms John Mascarenhas new Phase 2
2026-09-10 NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… University of West Attica new
2026-09-04 NCT07804901 Asciminib Frontline Risk Adapted Prof. Dr. med. Andreas Hochhaus new Phase 2
2026-08-11 NCT07758218 Allogeneic iNKT Cell Therapy (agenT-797) After SCT University of Wisconsin, Madison new Phase 1

Active trials by phase

Early Phase 1
1
Phase 1
33
Phase 1/2
12
Phase 2
66
Phase 3
9
Phase 4
3
Not charted: 55 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Chronic Myeloid Leukemia (CML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials